DK36392D0 - Anvendelse af kemisk forbindelse - Google Patents

Anvendelse af kemisk forbindelse

Info

Publication number
DK36392D0
DK36392D0 DK92363A DK36392A DK36392D0 DK 36392 D0 DK36392 D0 DK 36392D0 DK 92363 A DK92363 A DK 92363A DK 36392 A DK36392 A DK 36392A DK 36392 D0 DK36392 D0 DK 36392D0
Authority
DK
Denmark
Prior art keywords
chemical compound
glp
amide
combination
diabetes mellitus
Prior art date
Application number
DK92363A
Other languages
English (en)
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8092676&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK36392(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Priority to DK92363A priority Critical patent/DK36392D0/da
Publication of DK36392D0 publication Critical patent/DK36392D0/da
Priority to AT93907820T priority patent/ATE187647T1/de
Priority to US08/295,913 priority patent/US5631224A/en
Priority to US09/025,951 priority patent/USRE37302E1/en
Priority to PCT/DK1993/000099 priority patent/WO1993018786A1/en
Priority to AU38888/93A priority patent/AU3888893A/en
Priority to CN93104504A priority patent/CN1072504C/zh
Priority to DE69327309T priority patent/DE69327309T3/de
Priority to EP93907820A priority patent/EP0631505B2/en
Priority to JP51618293A priority patent/JP3579048B2/ja
Priority to US09/754,723 priority patent/US20010002394A1/en
Priority to US10/228,369 priority patent/US20030083259A1/en
Priority to JP2003196742A priority patent/JP2004002448A/ja
Priority to US11/478,107 priority patent/US20060247171A1/en
Priority to US11/485,692 priority patent/US20060247174A1/en
Priority to US11/725,262 priority patent/US20070225212A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
DK92363A 1992-03-19 1992-03-19 Anvendelse af kemisk forbindelse DK36392D0 (da)

Priority Applications (16)

Application Number Priority Date Filing Date Title
DK92363A DK36392D0 (da) 1992-03-19 1992-03-19 Anvendelse af kemisk forbindelse
JP51618293A JP3579048B2 (ja) 1992-03-19 1993-03-18 ペプチドの使用
US08/295,913 US5631224A (en) 1992-03-19 1993-03-18 Use of a peptide
AU38888/93A AU3888893A (en) 1992-03-19 1993-03-18 Use of a peptide
EP93907820A EP0631505B2 (en) 1992-03-19 1993-03-18 Use of a peptide
US09/025,951 USRE37302E1 (en) 1992-03-19 1993-03-18 Peptide
PCT/DK1993/000099 WO1993018786A1 (en) 1992-03-19 1993-03-18 Use of a peptide
AT93907820T ATE187647T1 (de) 1992-03-19 1993-03-18 Verwendung eines peptids
CN93104504A CN1072504C (zh) 1992-03-19 1993-03-18 肽的应用
DE69327309T DE69327309T3 (de) 1992-03-19 1993-03-18 Verwendung eines peptids
US09/754,723 US20010002394A1 (en) 1992-03-19 2001-01-04 Use of a peptide
US10/228,369 US20030083259A1 (en) 1992-03-19 2002-08-22 Use of a peptide
JP2003196742A JP2004002448A (ja) 1992-03-19 2003-07-14 ペプチドの使用
US11/478,107 US20060247171A1 (en) 1992-03-19 2006-06-29 Use of a peptide
US11/485,692 US20060247174A1 (en) 1992-03-19 2006-07-13 Use of a peptide
US11/725,262 US20070225212A1 (en) 1992-03-19 2007-03-19 Use of a peptide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK92363A DK36392D0 (da) 1992-03-19 1992-03-19 Anvendelse af kemisk forbindelse

Publications (1)

Publication Number Publication Date
DK36392D0 true DK36392D0 (da) 1992-03-19

Family

ID=8092676

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92363A DK36392D0 (da) 1992-03-19 1992-03-19 Anvendelse af kemisk forbindelse

Country Status (9)

Country Link
US (5) US5631224A (da)
EP (1) EP0631505B2 (da)
JP (2) JP3579048B2 (da)
CN (1) CN1072504C (da)
AT (1) ATE187647T1 (da)
AU (1) AU3888893A (da)
DE (1) DE69327309T3 (da)
DK (1) DK36392D0 (da)
WO (1) WO1993018786A1 (da)

Families Citing this family (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US7138486B2 (en) * 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
SK155694A3 (en) * 1992-06-15 1995-05-10 Pfizer Glucagon-like peptide, insulinotropin derivatives, method of their preparation, pharmaceutical agent containing and using these matters
US6558952B1 (en) * 1992-12-14 2003-05-06 Waratah Pharmaceuticals, Inc. Treatment for diabetes
US6284727B1 (en) * 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
GB9409496D0 (en) * 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US5574008A (en) * 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5834428A (en) * 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5912229A (en) * 1996-03-01 1999-06-15 Novo Nordisk Als Use of a pharmaceutical composition comprising an appetite-suppressing peptide
BR9707807A (pt) * 1996-03-01 1999-07-27 Novo Nordisk As Uso de uma composição farmacêutica composição farmacêutica processo de tratar doenças ou distúrbios associados com a regulação do apetite prejudicado e uso de um peptideo
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
ES2247676T3 (es) 1997-01-07 2006-03-01 Amylin Pharmaceuticals, Inc. Uso de las exendinas y de los agonistas de las mismas para la reduccion de la ingesta alimenticia.
US5981488A (en) * 1997-03-31 1999-11-09 Eli Lillly And Company Glucagon-like peptide-1 analogs
US7157555B1 (en) 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
ES2222613T3 (es) * 1997-09-12 2005-02-01 Pharis Biotec Gmbh Composicion para la terapia de diabetes mellitus y de la obesidad.
BR9815670A (pt) 1997-11-14 2000-10-17 Amylin Pharmaceuticals Inc Compostos agonistas de exendina
US7223725B1 (en) 1997-11-14 2007-05-29 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
EP1052994A2 (en) * 1998-02-02 2000-11-22 Trustees Of Tufts College Use of dipeptidylpetidase inhibitors to regulate glucose metabolism
DE69942307D1 (de) * 1998-02-27 2010-06-10 Novo Nordisk As N-terminal veränderte glp-1 abkömmlinge
EP1056775B1 (en) * 1998-02-27 2010-04-28 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
EP1060191B1 (en) * 1998-02-27 2010-04-28 Novo Nordisk A/S Derivatives of glp-1 analogs
EP1840134B1 (en) 1998-02-27 2016-04-13 Novo Nordisk A/S GLP-1 derivatives
JP2002508162A (ja) * 1998-02-27 2002-03-19 ノボ ノルディスク アクティーゼルスカブ Ｎ末端を短縮したｇｌｐ−１誘導体
AU3087599A (en) * 1998-03-19 1999-10-11 Bionebraska, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
US6998387B1 (en) 1998-03-19 2006-02-14 Amylin Pharmaceuticals, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
EP2332522A3 (en) 1998-03-19 2011-12-07 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
SI0974356T1 (en) 1998-07-15 2003-12-31 Merck Sante Tablets comprising a combination of metformin and glibenclamide
US20040037818A1 (en) * 1998-07-30 2004-02-26 Brand Stephen J. Treatment for diabetes
US6099862A (en) 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
EP1652531A1 (en) * 1998-09-24 2006-05-03 Eli Lilly &amp; Company Use of GLP-1 or Analogues in Treatment of Stroke
MY155270A (en) 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
RU2208015C2 (ru) * 1998-12-07 2003-07-10 Сосьете Де Консей Де Решерш Э Д'Аппликасьон Сьентифик Сас Аналоги гпп-1
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
AU5325200A (en) 1999-06-21 2001-01-09 Eli Lilly And Company Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat metabolic instability associated with non-insulin dependent diabetes
US9006175B2 (en) * 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
EP1196430B1 (en) 1999-06-29 2012-02-15 MannKind Corporation Purification and stabilization of peptide and protein pharmaceutical agents
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US20060160740A1 (en) * 1999-10-21 2006-07-20 Suad Efendic Use of GLP-1 or analogs in treatment of stroke
SK287810B6 (sk) 1999-11-03 2011-10-04 Bristol-Myers Squibb Company Farmaceutický prostriedok obsahujúci nízkodávkovú kombináciu metformínu a glyburidu
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
EP1234038A1 (en) * 1999-11-19 2002-08-28 Transkaryotic Therapies, Inc. Nucleic acid construct for optimized production of products
US20010036479A1 (en) 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
JP2003525908A (ja) * 2000-03-08 2003-09-02 ノボ ノルディスク アクティーゼルスカブ 血清脂質の低下
US20030040469A1 (en) * 2000-03-08 2003-02-27 Knudsen Liselotte Bjerre Lowering serum lipids
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
EP2055302B1 (en) * 2000-03-31 2014-09-10 Royalty Pharma Collection Trust Method for the improvement of islet signaling in diabetes mellitus and for its prevention
CA2405709A1 (en) * 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
US6866866B1 (en) * 2000-11-03 2005-03-15 Andrx Labs, Llc Controlled release metformin compositions
US20060034922A1 (en) * 2000-11-03 2006-02-16 Andrx Labs, Llc Controlled release metformin compositions
US6790459B1 (en) 2000-11-03 2004-09-14 Andrx Labs, Llc Methods for treating diabetes via administration of controlled release metformin
WO2002048192A2 (en) 2000-12-13 2002-06-20 Eli Lilly And Company Amidated glucagon-like peptide-1
AU2002306500C1 (en) * 2001-02-16 2006-09-28 Cellgate, Inc. Transporters comprising spaced arginine moieties
ATE318272T1 (de) 2001-04-11 2006-03-15 Bristol Myers Squibb Co Aminosäurekomplexe von c-arylglycosiden zur behandlung von diabetes und verfahren
US20030143191A1 (en) * 2001-05-25 2003-07-31 Adam Bell Chemokine beta-1 fusion proteins
US6642003B2 (en) 2001-08-02 2003-11-04 Cedars-Sinai Medical Center Human glucose-dependent insulin-secreting cell line
US7179788B2 (en) 2001-10-19 2007-02-20 Eli Lilly And Company Biphasic mixtures of GLP-1 and insulin
US6806381B2 (en) * 2001-11-02 2004-10-19 Bristol-Myers Squibb Company Process for the preparation of aniline-derived thyroid receptor ligands
EP1443919A4 (en) * 2001-11-16 2006-03-22 Bristol Myers Squibb Co DOUBLE INHIBITORS OF THE FATTY ACID BINDING PROTEIN OF THE ADIPOCYTES AND THE FATTY ACID BINDING PROTEIN OF KERATINOCYTES
EP2769715A3 (en) * 2001-11-26 2014-09-17 Trustees Of Tufts College Methods for treating autoimmune disorders, and reagents related thereto
CA2468192A1 (en) * 2001-11-26 2003-06-05 Trustees Of Tufts College Peptidomimetic inhibitors of post-proline cleaving enzymes
CA2471363C (en) * 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
CN1332711C (zh) * 2002-02-20 2007-08-22 埃米球科技有限公司 施用glp－1分子的方法
US7141240B2 (en) * 2002-03-12 2006-11-28 Cedars-Sinai Medical Center Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1
ES2425392T3 (es) 2002-03-20 2013-10-15 Mannkind Corporation Cartucho para un aparato de inhalación
JP4478563B2 (ja) * 2002-05-14 2010-06-09 プレゼント インヴェストメンツ エルエルシー 送信信号の形成方法
US20040052848A1 (en) * 2002-05-23 2004-03-18 Xiu-Xiu Cheng Biguanide formulations
IL165242A0 (en) * 2002-05-24 2005-12-18 Waratah Pharmaceuticals Inc Treatment for diabetes
ES2334268T3 (es) 2002-06-07 2010-03-08 Waratah Pharmaceuticals, Inc. Procedimientos y composiciones para el tratamiento de la diabetes.
DE60327771D1 (de) * 2002-07-04 2009-07-09 Zealand Pharma As Glp-1 und behandlungsmethode für diabetes
US20080260838A1 (en) * 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
EP1546200A2 (en) 2002-10-02 2005-06-29 Zealand Pharma A/S Stabilized exendin-4 compounds
DE60326002D1 (de) * 2002-10-22 2009-03-12 Waratah Pharmaceuticals Inc Behandlung von diabetes.
ES2344057T3 (es) * 2002-10-23 2010-08-17 Bristol-Myers Squibb Company Inhibidores de la dipeptidil peptidasa iv basados en nitrilos de glicina.
TW200504021A (en) * 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
JP2006516620A (ja) * 2003-01-24 2006-07-06 ブリストル−マイヤーズ　スクイブ　カンパニー 甲状腺受容体におけるシクロアルキル含有アニリドリガンド
US7459474B2 (en) 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US6995183B2 (en) * 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
US7371759B2 (en) * 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7576121B2 (en) * 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7317109B2 (en) * 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
WO2005047297A1 (en) * 2003-11-12 2005-05-26 Phenomix Corporation Heterocyclic boronic acid compounds
US7767828B2 (en) 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US20060286129A1 (en) * 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
BRPI0507189A (pt) * 2004-01-30 2007-06-26 Waratah Pharmaceuticals Inc uso combinado de um agonista de glp-1 e compostos de gastrina
US7786163B2 (en) * 2004-07-12 2010-08-31 Forest Laboratories Holdings Limited (BM) Constrained cyano compounds
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
PL1791542T3 (pl) 2004-08-23 2015-11-30 Mannkind Corp Sole diketopiperazyny do dostarczania leków
AR051446A1 (es) * 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
US7589088B2 (en) * 2004-12-29 2009-09-15 Bristol-Myers Squibb Company Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US7635699B2 (en) * 2004-12-29 2009-12-22 Bristol-Myers Squibb Company Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US7317024B2 (en) 2005-01-13 2008-01-08 Bristol-Myers Squibb Co. Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US20090142338A1 (en) * 2005-03-04 2009-06-04 Curedm, Inc. Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
EP1858545A2 (en) * 2005-03-04 2007-11-28 Curedm Inc. Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
US7521557B2 (en) 2005-05-20 2009-04-21 Bristol-Myers Squibb Company Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
US7393919B2 (en) 2005-05-25 2008-07-01 Cure Dm, Inc. Peptides, derivatives and analogs thereof, and methods of using same
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7888381B2 (en) 2005-06-14 2011-02-15 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
AU2006290870B2 (en) 2005-09-14 2013-02-28 Mannkind Corporation Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces
EP1943215A2 (en) 2005-10-31 2008-07-16 Brystol-Myers Squibb Company Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase iv and methods
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
EP2497484A3 (en) 2006-02-22 2012-11-07 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US20070238770A1 (en) * 2006-04-05 2007-10-11 Bristol-Myers Squibb Company Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
US7795291B2 (en) 2006-07-07 2010-09-14 Bristol-Myers Squibb Company Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
EP2099767A1 (en) 2006-11-01 2009-09-16 Brystol-Myers Squibb Company Modulators of glucocorticoid receptor, ap-1, and/or nf- b activity and use thereof
WO2008057855A2 (en) 2006-11-01 2008-05-15 Bristol-Myers Squibb Company Heterocyclic compounds as modulators of glucocorticoid receptor, ap-i, and/or np-kappa-b activity
WO2008057862A2 (en) 2006-11-01 2008-05-15 Bristol-Myers Squibb Company MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-&kappav;B ACTIVITY AND USE THEREOF
WO2008064306A2 (en) * 2006-11-22 2008-05-29 Curedm, Inc. Methods and compositions relating to islet cell neogenesis
KR100860561B1 (ko) * 2007-05-02 2008-09-26 경희대학교 산학협력단 컴파운드 ｋ 및 메트포민을 유효성분으로 포함하는당뇨병의 예방 및 치료용 약학적 조성물
KR20100080519A (ko) * 2007-08-30 2010-07-08 큐어디엠 인코포레이티드 프로섬 펩타이드 및 이의 유사체의 조성물 및 이의 이용 방법
CA2703338A1 (en) * 2007-10-24 2009-04-30 Mannkind Corporation Method of preventing adverse effects by glp-1
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
MX2010004508A (es) * 2007-10-24 2010-07-02 Mannkind Corp Suministro de agentes activos.
EP2209780B1 (en) 2007-11-01 2014-01-01 Bristol-Myers Squibb Company Nonsteroidal compounds useful as modulators of glucocorticoid receptor ap-1 and/or nf- kappa b activity and use thereof
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
DK2570147T3 (da) 2008-06-13 2018-01-29 Mannkind Corp Tørpulverinhalator og system til lægemiddelindgivelse
KR101628410B1 (ko) 2008-06-20 2016-06-08 맨카인드 코포레이션 흡입 활동에 관한 실시간 프로파일링을 위한 대화형 장치 및 방법
CN102149710A (zh) 2008-06-24 2011-08-10 百时美施贵宝公司 糖皮质激素受体、AP-1和/或NF-κB 活性的环戊噻吩调节剂及其用途
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
GB0817969D0 (en) * 2008-10-01 2008-11-05 Axcess Ltd Pharmaceutical composition
WO2010043566A2 (de) 2008-10-17 2010-04-22 Sanofi-Aventis Deutschland Gmbh Kombination von einem insulin und einem glp-1-agonisten
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
CA2754595C (en) 2009-03-11 2017-06-27 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
US8790916B2 (en) * 2009-05-14 2014-07-29 Genestream, Inc. Microfluidic method and system for isolating particles from biological fluid
US8734845B2 (en) 2009-06-12 2014-05-27 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
CA2778698A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
US9707176B2 (en) 2009-11-13 2017-07-18 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist and methionine
ES2855146T3 (es) 2009-11-13 2021-09-23 Sanofi Aventis Deutschland Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
EP2504019A2 (en) 2009-11-25 2012-10-03 ArisGen SA Mucosal delivery composition comprising a peptide complexed with a crown compound and/or a counter ion
WO2011123943A1 (en) 2010-04-09 2011-10-13 Mount Sinai Hospital Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
MX343360B (es) 2010-04-27 2016-11-03 Zealand Pharma As Conjugados peptidicos de agonistas del receptor de glp-1 y gastrina y su uso.
RU2531455C2 (ru) 2010-06-21 2014-10-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
AU2011276254B2 (en) 2010-07-09 2016-11-03 James Trinca Green Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin
PT2611458T (pt) 2010-08-30 2016-12-16 Sanofi Aventis Deutschland Utilização de ave0010 para o fabrico de um medicamento para o tratamento da diabetes mellitus tipo 2
CN102643339B (zh) * 2011-02-21 2014-04-09 天津药物研究院 一种glp-1类似物、制备方法及其应用
MY180552A (en) 2011-04-01 2020-12-02 Mannkind Corp Blister package for pharmaceutical cartridges
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
EP2526971A1 (en) 2011-05-25 2012-11-28 ArisGen SA Mucosal delivery of drugs
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
PT2750699E (pt) 2011-08-29 2015-11-03 Sanofi Aventis Deutschland Acelerómetro pendular
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
WO2013063160A1 (en) 2011-10-24 2013-05-02 Mannkind Corporation Methods and compositions for treating pain
CN104144704B (zh) 2011-11-03 2018-03-23 西兰制药公司 Glp‑1受体激动剂肽胃泌素缀合物
CA2878457C (en) 2012-07-12 2021-01-19 Mannkind Corporation Dry powder drug delivery systems and methods
AR091866A1 (es) 2012-07-23 2015-03-04 Zealand Pharma As Analogos del glucagon
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
BR112015023168B1 (pt) 2013-03-15 2021-08-10 Mannkind Corporation Composição de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina cristalina, método de produção de partículas de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina e uso de uma composição de dicetopiperazina cristalina
CN114848614A (zh) 2013-07-18 2022-08-05 曼金德公司 热稳定性干粉药物组合物和方法
CA2920488C (en) 2013-08-05 2022-04-26 Mannkind Corporation Insufflation apparatus and methods
US9593113B2 (en) 2013-08-22 2017-03-14 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
UA122767C2 (uk) 2013-10-17 2021-01-06 Зіленд Фарма А/С Ацильований аналог глюкагону
CA2929459C (en) 2013-11-06 2022-05-03 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
EA035688B1 (ru) 2013-11-06 2020-07-27 Зилэнд Фарма А/С Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip
CN112957455A (zh) 2014-01-09 2021-06-15 赛诺菲 胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂
SG11201604706TA (en) 2014-01-09 2016-07-28 Sanofi Sa Stabilized pharmaceutical formulations of insulin aspart
WO2015104311A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
BR112017008659A2 (pt) 2014-10-29 2018-01-30 Zealand Pharma As ?métodos e compostos de agonista de gip?
CN107206058A (zh) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
AU2016247499B2 (en) 2015-04-16 2020-09-03 Zealand Pharma A/S Acylated glucagon analogue
CN117384274A (zh) 2016-12-09 2024-01-12 西兰制药公司 酰化的glp-1/glp-2双重激动剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312924A (en) * 1983-12-30 1994-05-17 Dr. Karl Thomae Gmbh Phenylacetic acid benzylamides
US5216167A (en) * 1983-12-30 1993-06-01 Dr. Karl Thomae Gmbh Phenylacetic acid benzylamides
CA1341320C (en) * 1986-05-05 2001-11-20 Joel Habener Insulinotropic hormone
EP0464022B1 (en) * 1989-03-20 2000-05-31 The General Hospital Corporation Insulinotropic hormone
DE69129226T2 (de) * 1990-01-24 1998-07-30 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
USRE37302E1 (en) * 1992-03-19 2001-07-31 Novo Nordisk A/S Peptide

Also Published As

Publication number Publication date
DE69327309T3 (de) 2007-07-05
EP0631505A1 (en) 1995-01-04
US20060247171A1 (en) 2006-11-02
JP3579048B2 (ja) 2004-10-20
US5631224A (en) 1997-05-20
CN1072504C (zh) 2001-10-10
DE69327309T2 (de) 2000-07-13
JPH07504670A (ja) 1995-05-25
ATE187647T1 (de) 2000-01-15
EP0631505B2 (en) 2006-11-29
US20030083259A1 (en) 2003-05-01
CN1088835A (zh) 1994-07-06
US20010002394A1 (en) 2001-05-31
WO1993018786A1 (en) 1993-09-30
AU3888893A (en) 1993-10-21
EP0631505B1 (en) 1999-12-15
DE69327309D1 (de) 2000-01-20
JP2004002448A (ja) 2004-01-08
US20060247174A1 (en) 2006-11-02

Similar Documents

Publication Publication Date Title
DK36392D0 (da) Anvendelse af kemisk forbindelse
DE68929217T2 (de) Insulinotropes hormon
DK0964873T3 (da) Anvendelse af glucagonlignende peptid-1 (GLP-1) eller analoger til ophævelse af kataboliske ændringer efter kirurgi
DK0627163T3 (da) Fungicide kombinationer af aktive stoffer
EA200300026A1 (ru) Аналоги глюкагоноподобного пептида-1
BR0112519A (pt) Derivados anticonvulsivantes úteis para prevenir o desenvolvimento de diabetes melito do tipo ii e sìndrome x
DK0996444T3 (da) Behandling af diabetes med thiazolidindion og metformin
WO2003018516A3 (en) Glucagon-like peptide-1 analogs
DK1001783T3 (da) Behandling af diabetes med thiazolidindion, insulinsekretagog og biguanid
ES2117243T3 (es) Nuevos antioxidantes fenolicos liquidos.
FI951511A (fi) IL-10:n käyttö insuliinista riippuvan diabetes mellituksen ennaltaestoon tai hoitoon
ES2163531T3 (es) Carboxilatos de aminoguanidina para el tratamiento de diabetes mellitus no insulinodependiente.
DK0550895T3 (da) 4,13-dioxabicyclo(8.2.1)-tridecenonderivater, fremgangsmåde og mellemprodukter til fremstilling deraf og lægemidler, der indeholder disse forbindelser
DK0607278T3 (da) Fremgangsmåde til forstærkning af tarmabsorption
DK0796618T3 (da) Behandling og profylakse af pankreatitis
TR200000133T2 (tr) Tiazolidinedion, ensülin salgılattırıcısı ve alfa glükosidaz inhibitörü ile diabetin (şeker hastasının) tedavisi.
WO2001080871A3 (de) Anwendung von guanylat-zyklase-c (gc-c) agonisten als insulinotrope faktoren zur behandlung von diabetes mellitus typ 2
KR960702835A (ko) 헤테로사이클릭 화학(Heterocyclic chemistry)
DE69625210T2 (de) Nicorandil gegen angstneurosen
ES2084733T3 (es) Nuevos substratos de beta-galactosidasa para el analisis cedia.
DK0714393T3 (da) Thiazoler som antiviralt middel
WO2003003971A3 (fr) Utilisation d&#39;agents antidiabetiques pour fabriquer un medicament ayant un effet cicatrisant
TSUNOOKA The Society of Polymer Science
UA88862C2 (en) Glucagon-like peptide-1 analogs
BR9710170A (pt) Processo de preparação de 2,2&#39;-(1-metil-1,2-etano-dilideno)bis(hidrazina carboximido)

Legal Events

Date Code Title Description
ATS Application withdrawn